AI Article Synopsis
- - The Pediatric Preclinical Testing Program investigated the effectiveness of the EZH2 inhibitor tazemetostat (EPZ6438) on rhabdoid tumor models, which are aggressive childhood cancers.
- - Researchers studied whether combining another EZH2 inhibitor, EPZ011989, with standard chemotherapy drugs (irinotecan, vincristine, and cyclophosphamide) could improve treatment outcomes.
- - While EPZ011989 led to longer times before disease progression in all models tested, it did not shrink tumors and only occasionally improved outcomes when used with standard chemotherapy.
Article Abstract
The Pediatric Preclinical Testing Program (PPTP) previously reported the activity of the EZH2 inhibitor tazemetostat (EPZ6438) against xenograft models of rhabdoid tumors. Here, we determined whether an inhibitor of EZH2 enhanced the effect of standard of care chemotherapeutic agents: irinotecan, vincristine, and cyclophosphamide. EPZ011989 significantly prolonged time to event in all the six rhabdoid models studied but did not induce tumor regression. The addition of EPZ011989 to standard of care agents significantly improved time to event in at least one model for each of the agents studied, although this effect was observed in only a minority of the combination testing experiments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276573 | PMC |
| http://dx.doi.org/10.1002/pbc.28772 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!